{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:24:14Z","timestamp":1790778254649,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T00:00:00Z","timestamp":1566950400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T00:00:00Z","timestamp":1566950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000030","name":"Associazione Italiana per la Ricerca sul Cancro (AIRC) \"Programma di ricerca 5 per Mille 2018\"","doi-asserted-by":"publisher","award":["Id.21073"],"award-info":[{"award-number":["Id.21073"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12967-019-2039-4","type":"journal-article","created":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T04:17:03Z","timestamp":1566965823000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Mutational concordance between primary and metastatic melanoma: a next-generation sequencing approach"],"prefix":"10.1186","volume":"17","author":[{"name":"Melanoma Unit of Sassari (MUS)","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Manca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Italian Association for Cancer Research (AIRC) Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Italian Melanoma Intergroup (IMI)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Paliogiannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Colombino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"Casula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Lissia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Botti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Carac\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo A.","family":"Ascierto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"Sini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Palomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Pisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Doneddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cossu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4350-2276","authenticated-orcid":false,"given":"Giuseppe","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,28]]},"reference":[{"key":"2039_CR1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/CEJ.0000000000000223","volume":"26","author":"A Cossu","year":"2017","unstructured":"Cossu A, Casula M, Cesaraccio R, Lissia A, Colombino M, Sini MC, et al. Epidemiology and genetic susceptibility of malignant melanoma in North Sardinia, Italy. Eur J Cancer Prev. 2017;26:263\u20137.","journal-title":"Eur J Cancer Prev."},{"key":"2039_CR2","unstructured":"SEER Cancer statistics review 1975-2015. \n                    https:\/\/seer.cancer.gov\/csr\/1975_2015\/results_merged\/sect_16_melanoma_skin.pdf\n                    \n                  . Accessed 01 May 2019."},{"key":"2039_CR3","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/978-3-319-78310-9_32","volume-title":"Melanoma. A modern multidisciplinary approach","author":"CY Hung","year":"2018","unstructured":"Hung CY, Chang JWC. Chemotherapy and biochemotherapy for melanoma. In: Riker A, editor. Melanoma. A modern multidisciplinary approach. Basel: Springer International Publishing AG; 2018. p. 525\u201331."},{"key":"2039_CR4","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","volume":"392","author":"D Schadendorf","year":"2018","unstructured":"Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, et al. Melanoma. Lancet. 2018;392:971\u201384.","journal-title":"Lancet"},{"key":"2039_CR5","doi-asserted-by":"publisher","first-page":"4317","DOI":"10.1245\/s10434-014-3799-y","volume":"21","author":"A Gos","year":"2014","unstructured":"Gos A, Jurkowska M, van Akkooi A, Robert C, Kosela-Paterczyk H, Koljenovi\u0107 S, et al. Molecular characterization and patient outcome of melanoma nodal metastases and an unknown primary site. Ann Surg Oncol. 2014;21:4317\u201323.","journal-title":"Ann Surg Oncol"},{"key":"2039_CR6","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1200\/JCO.2011.41.2452","volume":"30","author":"M Colombino","year":"2012","unstructured":"Colombino M, Capone M, Lissia A, Cossu A, Rubino C, De Giorgi V, et al. BRAF\/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol. 2012;30:2522\u20139.","journal-title":"J Clin Oncol"},{"key":"2039_CR7","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.1038\/jid.2015.229","volume":"135","author":"E Riveiro-Falkenbach","year":"2015","unstructured":"Riveiro-Falkenbach E, Villanueva CA, Garrido MC, Ruano Y, Garcia-Martin RM, Godoy E, et al. Intra- and inter-tumoral homogeneity of BRAF(V600E) mutations in melanoma tumors. J Investig Dermatol. 2015;135:3078\u201385.","journal-title":"J Investig Dermatol."},{"key":"2039_CR8","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.yexmp.2014.09.008","volume":"97","author":"M Saroufim","year":"2014","unstructured":"Saroufim M, Habib RH, Gerges R, Saab J, Loya A, Amr SS, et al. Comparing BRAF mutation status in matched primary and metastatic cutaneous melanomas: implications on optimized targeted therapy. Exp Mol Pathol. 2014;97:315\u201320.","journal-title":"Exp Mol Pathol."},{"key":"2039_CR9","first-page":"6483","volume":"9","author":"K Omholt","year":"2003","unstructured":"Omholt K, Platz A, Kanter L, Ringborg U, Hansson J. NRAS, and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res. 2003;9:6483\u20138.","journal-title":"Clin Cancer Res"},{"key":"2039_CR10","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/sj.bjc.6606072","volume":"104","author":"J Lin","year":"2011","unstructured":"Lin J, Goto Y, Murata H, Sakaizawa K, Uchiyama A, Saida T, et al. Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression. Br J Cancer. 2011;104:464\u20138.","journal-title":"Br J Cancer"},{"key":"2039_CR11","doi-asserted-by":"publisher","first-page":"8531","DOI":"10.18632\/oncotarget.23989","volume":"9","author":"MC Sini","year":"2018","unstructured":"Sini MC, Doneddu V, Paliogiannis P, Casula M, Colombino M, Manca A, et al. Genetic alterations in main candidate genes during melanoma progression. Oncotarget. 2018;9:8531\u201341.","journal-title":"Oncotarget."},{"key":"2039_CR12","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s11912-018-0733-7","volume":"20","author":"G Palmieri","year":"2018","unstructured":"Palmieri G, Colombino M, Casula M, Manca A, Mandal\u00e0 M, Cossu A, et al. Molecular pathways in melanomagenesis: what we learned from next-generation sequencing approaches. Curr Oncol Rep. 2018;20:86.","journal-title":"Curr Oncol Rep."},{"key":"2039_CR13","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","volume":"161","author":"Cancer Genome Atlas Network","year":"2015","unstructured":"Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell. 2015;161:1681\u201396.","journal-title":"Cell"},{"key":"2039_CR14","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nature22071","volume":"545","author":"NK Hayward","year":"2017","unstructured":"Hayward NK, Wilmott JS, Waddell N, Johansson PA, Field MA, Nones K, et al. Whole-genome landscapes of major melanoma subtypes. Nature. 2017;545:175\u201380.","journal-title":"Nature"},{"key":"2039_CR15","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1038\/ng.2359","volume":"44","author":"M Krauthammer","year":"2012","unstructured":"Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker JP, et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet. 2012;44:1006\u201314.","journal-title":"Nat Genet"},{"key":"2039_CR16","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","volume":"150","author":"E Hodis","year":"2012","unstructured":"Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, et al. A landscape of driver mutations in melanoma. Cell. 2012;150:251\u201363.","journal-title":"Cell"},{"key":"2039_CR17","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/nature11071","volume":"485","author":"MF Berger","year":"2012","unstructured":"Berger MF, Hodis E, Heffernan TP, Deribe YL, Lawrence MS, Protopopov A, et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature. 2012;485:502\u20136.","journal-title":"Nature"},{"key":"2039_CR18","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3389\/fonc.2015.00183","volume":"5","author":"G Palmieri","year":"2015","unstructured":"Palmieri G, Ombra M, Colombino M, Casula M, Sini M, Manca A, et al. Multiple molecular pathways in melanomagenesis: characterization of therapeutic targets. Front Oncol. 2015;5:183.","journal-title":"Front Oncol."},{"key":"2039_CR19","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.tranon.2017.09.007","volume":"10","author":"TM Grzywa","year":"2017","unstructured":"Grzywa TM, Paskal W, W\u0142odarski PK. Intratumor and intertumor heterogeneity in melanoma. Transl Oncol. 2017;10:956\u201375.","journal-title":"Transl Oncol."},{"key":"2039_CR20","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1158\/1541-7786.MCR-18-0601","volume":"17","author":"F Chen","year":"2019","unstructured":"Chen F, Zhang Y, Varambally S, Creighton CJ. Molecular correlates of metastasis by systematic pan-cancer analysis across The Cancer Genome Atlas. Mol Cancer Res. 2019;17:476\u201387.","journal-title":"Mol Cancer Res"},{"key":"2039_CR21","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.ad.2016.12.025","volume":"108","author":"E Godoy-Gij\u00f3n","year":"2017","unstructured":"Godoy-Gij\u00f3n E, Yuste-Chaves M, Santos-Briz \u00c1. BRAF mutation status concordance between primary cutaneous melanomas and corresponding metastases: a review of the latest evidence. Actas Dermosifiliogr. 2017;108:894\u2013901.","journal-title":"Actas Dermosifiliogr."},{"key":"2039_CR22","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41598-017-00606-w","volume":"7","author":"Bustos B de Unamuno","year":"2017","unstructured":"de Unamuno Bustos B, Murria Estal R, P\u00e9rez Sim\u00f3 G, de Juan Jimenez I, Escutia Mu\u00f1oz B, Rodr\u00edguez Serna M, et al. Towards personalized medicine in melanoma: implementation of a clinical next-generation sequencing panel. Sci Rep. 2017;7:495.","journal-title":"Sci Rep."},{"key":"2039_CR23","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12885-017-3149-0","volume":"17","author":"A Reiman","year":"2017","unstructured":"Reiman A, Kikuchi H, Scocchia D, Smith P, Tsang YW, Snead D, et al. Validation of an NGS mutation detection panel for melanoma. BMC Cancer. 2017;17:150.","journal-title":"BMC Cancer."},{"key":"2039_CR24","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/jid.2014.366","volume":"135","author":"AE Siroy","year":"2015","unstructured":"Siroy AE, Boland GM, Milton DR, Roszik J, Frankian S, Malke J, et al. Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Investig Dermatol. 2015;135:508\u201315.","journal-title":"J Investig Dermatol."},{"key":"2039_CR25","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1016\/j.jid.2016.05.103","volume":"136","author":"M Casula","year":"2016","unstructured":"Casula M, Colombino M, Manca A, Carac\u00f2 C, Botti G, Ascierto PA, et al. Low levels of genetic heterogeneity in matched lymph node metastases from patients with melanoma. J Investig Dermatol. 2016;136:1917\u201320.","journal-title":"J Investig Dermatol."},{"key":"2039_CR26","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ccell.2018.06.005","volume":"34","author":"AH Shain","year":"2018","unstructured":"Shain AH, Joseph NM, Yu R, Benhamida J, Liu S, Prow T, et al. Genomic and transcriptomic analysis reveals incremental disruption of key signaling pathways during melanoma evolution. Cancer Cell. 2018;34:45\u201355.","journal-title":"Cancer Cell"},{"key":"2039_CR27","doi-asserted-by":"publisher","first-page":"12297","DOI":"10.18632\/oncotarget.3655","volume":"6","author":"H Cirenajwis","year":"2015","unstructured":"Cirenajwis H, Ekedahl H, Lauss M, Harbst K, Carneiro A, Enoksson J, et al. Molecular stratification of metastatic melanoma using gene expression profiling: prediction of survival outcome and benefit from molecular targeted therapy. Oncotarget. 2015;6:12297\u2013309.","journal-title":"Oncotarget."},{"key":"2039_CR28","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.yexmp.2017.08.006","volume":"103","author":"AP Miraflor","year":"2017","unstructured":"Miraflor AP, de Abreu FB, Peterson JD, Turner SA, Amos CI, Tsongalis GJ, et al. Somatic mutation analysis in melanoma using targeted next generation sequencing. Exp Mol Pathol. 2017;103:172\u20137.","journal-title":"Exp Mol Pathol"},{"key":"2039_CR29","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Cutaneous melanoma version 2.2019\u2014March 12, 2019. \n                    https:\/\/www.nccn.org\/professionals\/physician_gls\/default.aspx\n                    \n                  . Accessed 01 May 2019."},{"key":"2039_CR30","unstructured":"Linee Guida AIOM 2018. Melanoma. \n                    https:\/\/www.aiom.it\/linee-guida\/linee-guida-aiom-2018-melanoma\/\n                    \n                  . Accessed 01 May 2019."},{"key":"2039_CR31","doi-asserted-by":"publisher","first-page":"e8404","DOI":"10.1097\/MD.0000000000008404","volume":"96","author":"EJ Hannan","year":"2017","unstructured":"Hannan EJ, O\u2019Leary DP, MacNally SP, Kay EW, Farrell MA, Morris PG, et al. The significance of BRAF V600E mutation status discordance between primary cutaneous melanoma and brain metastases: the implications for BRAF inhibitor therapy. Medicine. 2017;96:e8404.","journal-title":"Medicine"},{"key":"2039_CR32","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1186\/1471-2407-9-352","volume":"9","author":"C Casula","year":"2009","unstructured":"Casula C, Muggiano A, Cossu A, Budroni M, Carac\u00f2 C, Ascierto PA, et al. Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy. BMC Cancer. 2009;9:352.","journal-title":"BMC Cancer"},{"key":"2039_CR33","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/1479-5876-10-178","volume":"10","author":"G Palomba","year":"2012","unstructured":"Palomba G, Colombino M, Contu A, Massidda B, Baldino G, Pazzola A, et al. Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia. J Transl Med. 2012;10:178.","journal-title":"J Transl Med"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-019-2039-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12967-019-2039-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-019-2039-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T23:15:32Z","timestamp":1598483732000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-019-2039-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,28]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["2039"],"URL":"https:\/\/doi.org\/10.1186\/s12967-019-2039-4","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,28]]},"assertion":[{"value":"5 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All the patients gave their informed consent for the anonymous use of their clinical data for the purposes of the study. The study was approved by the Committee for the Ethics of the Research and Bioethics of the National Research Council (CNR).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Paolo A. Ascierto has\/had a consultant and advisory role for Bristol Myers Squibb, Incyte, Merck Sharp & Dohme, Roche-Genentech, Novartis, Amgen, Array, Merck-Serono, and Pierre Fabre. He received research fund from Bristol Myers Squibb, Roche-Genetech, and Array. Giuseppe Palmieri has\/had an advisory role for Bristol Myers Squibb, Incyte, Merck Sharp & Dohme, Novartis, Pierre Fabre, and Roche-Genetech. All the remaining authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"289"}}